Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma S.A. (OTCMKTS:IPHYF) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 4,900 shares, a decline of 21.0% from the August 15th total of 6,200 shares. Based on an average daily trading volume, of 200 shares, the days-to-cover ratio is currently 24.5 days.

Innate Pharma Price Performance

Shares of IPHYF remained flat at $2.30 during mid-day trading on Tuesday. The company’s 50-day moving average price is $2.10 and its two-hundred day moving average price is $2.33. Innate Pharma has a 52 week low of $1.93 and a 52 week high of $3.00.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.